Fidelity Management & Research Co recently announced the acquisition of new stake in Royalty Pharma plc (NASDAQ:RPRX). The institutional investor has increased its shareholding in the Healthcare company by 2.31% to 41.25 million shares with purchase of 0.93 million shares. This fresh investment now brings its stake to 9.31% valued currently at $1.48 billion. In addition, The Vanguard Group, Inc. raised its holdings by 0.64 million to 34.83 million shares. And BlackRock Fund Advisors has lifted its position by 6.04% or 0.77 million shares – to 13.54 million shares.
With over 2.52 million Royalty Pharma plc (RPRX) shares trading Monday and a closing price of $32.77 on the day, the dollar volume was approximately $82.53 million. The shares have shown a negative half year performance of -24.89% and its price on 03/13/23 lost nearly -1.00%. Currently, there are 442.23M common shares owned by the public and among those 167.01M shares have been available to trade.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 8 analysts who have offered their price forecasts for RPRX have a consensus price objective of $52.88. The analysts have set the share’s price value over the next 12 months at a high of $60.00 and a low of $47.00. The average price target is 38.15% above its recent price level and an upside to the estimated low will see the stock gain 30.28% over that period. But an upside of 45.38% will see the stock hit the forecast high price target while median target price for the stock is $52.50.
The top 3 mutual fund holders in Royalty Pharma plc are Vanguard Total Stock Market Index, Vanguard Mid Cap Index Fund, and Morgan Stanley Instl. Fund-Growth. Vanguard Total Stock Market Index owns 11.49 million shares of the company’s stock, all valued at over $411.75 million. The company bought an additional 84166.0 shares recently to bring their total holdings to about 2.59% of the shares outstanding. Vanguard Mid Cap Index Fund bought 14061.0 shares to see its total holdings expand to 8.73 million shares valued at over $313.06 million and representing 1.97% of the shares outstanding. Morgan Stanley Instl. Fund-Growth sold -1.06 million shares to bring its total holdings to over 8.22 million shares at a value of $294.67 million. Morgan Stanley Instl. Fund-Growth now owns shares totaling to 1.86% of the shares outstanding.
Shares of Royalty Pharma plc (NASDAQ: RPRX) opened at $33.08, down -$0.02 from a prior closing price of $33.10. However, the script later moved the day high at 33.56, down -1.00%. The company’s stock has a 5-day price change of -6.77% and -22.58% over the past three months. RPRX shares are trading -17.08% year to date (YTD), with the 12-month market performance down to -14.91% lower. It has a 12-month low price of $32.92 and touched a high of $44.75 over the same period. RPRX has an average intraday trading volume of 1.66 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -9.46%, -13.22%, and -19.96% respectively.
Institutional ownership of Royalty Pharma plc (NASDAQ: RPRX) shares accounts for 68.40% of the company’s 442.23M shares outstanding. Mutual fund holders own 35.70%, while other institutional holders and individual stakeholders account for 41.03% and 26.51% respectively.
It has a market capitalization of $20.15B. The stock’s trailing 12-month PE ratio is 297.91, while the earnings-per-share (ttm) stands at $0.11. The company has a PEG of 31.19 and a Quick Ratio of 2.20 with the debt-to-equity ratio at 1.26. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.66% over the week and 1.98% over the month.
Analysts forecast that Royalty Pharma plc (RPRX) will achieve an EPS of $1.52 for the current quarter, $0.8 for the next quarter and $3.66 for 2023. The lowest estimate earnings-per-share for the quarter is $1.31 while analysts give the company a high EPS estimate of $1.61. Comparatively, EPS for the current quarter was $0.8 a year ago. Earnings per share for the fiscal year are expected to decrease by -93.50%, and -4.30% over the next financial year. EPS should grow at an annualized rate of 9.55% over the next five years, compared to -45.50% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate Royalty Pharma plc (RPRX) as a “Strong Buy” at a consensus score of 1.90. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 0 of the 8 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the RPRX, a number of firms have released research notes about the stock. UBS stated their Buy rating for the stock in a research note on June 14, 2022, with the firm’s price target at $47. Scotiabank coverage for the Royalty Pharma plc (RPRX) stock in a research note released on May 13, 2022 offered a Sector Outperform rating with a price target of $53. Goldman was of a view on April 27, 2022 that the stock is Buy, while JP Morgan gave the stock Overweight rating on April 14, 2022, issuing a price target of $50. Morgan Stanley on their part issued Overweight rating on April 06, 2022.
